The results of a study by researchers at the University of Texas Medical Branch may pave the way for a new medicine delivery system that could reduce the incidence of pre-term labor and premature birth by allowing physicians to treat the ‘fetus as the patient’.
It has long been suspected that pre-term labor is triggered by inflammation caused by a sick fetus. A new study by scientists at UTMB has proved the hypothesis by studying several important assumptions about the relationship between the health of a mother and her unborn child.
According to Dr. Ramkumar Menon, a Professor in UTMB’s Department of Obstetrics and Gynecology and Cell Biology, his team worked with ILIAS Biologics, Inc., a South Korean biotechnology company, to test their bioengineered exosomes as a delivery system for anti-inflammatory medicine directly to the fetus.
“Exosomes are natural nanoparticles or vesicles in our bodies, and we have trillions of them circulating through us at all times. By packaging the medicine inside a bioengineered exosome and injecting it into the mother intravenously, the exosomes travel through the blood system, cross the placental barrier and arrive in the fetus, where they deliver the medicine,” explains Dr. Menon.
In laboratory tests with mice, there were several steps prior to testing the drug delivery. First, Menon said it was important to prove that fetal cells, specifically immune cells, actually migrated through the mother’s body to her uterine tissues as well as to her, which can cause inflammation, the leading cause of pre-term labor.
To prove migration of cells, female mice were mated with male mice who had been genetically engineered with a red fluorescent dye called tdtomato. The dye causes cells in the male to turn red, so once mating has occurred, cells in the developing fetus also turn red and can easily be tracked as they migrate through the mother.
This model was developed by Dr. Sheller-Miller, a post-doctoral fellow in the Menon lab who is also the first author of this report. Development of this model that determined fetal immune cells reaching maternal tissues was also a turning point in this research.
Once scientists had proof of cell migration, they next used the mouse model to determine if bioengineered exosomes could deliver a special anti-inflammatory medicine, an inhibitor of NF-kB, called super repressor (SR) IkB from the mother’s bloodstream to the fetus.
The exosomes were created using an innovative approach developed by ILIAS Biologics, Inc. called EXPLOR, or Exosomes engineering for Protein Loading via Optically Reversible protein to protein interaction.The study proved that the exosomes effectively delivered medicine to the fetus, slowed the migration of fetal immune cells, and delayed pre-term labor.
In addition, the study found that:
- Sustained effects/delays in labor required repeated dosing
- Prolongation of gestation improved pup viability
- Mouse models provided valuable information to help understand the mechanisms often seen in humans
- Future studies, including human clinical trials are needed to confirm laboratory results
“Pre-term birth rates have not reduced in the past few decades, and this technology (the bioengineered exosomes) could lead the way to other treatments for the delivery of drugs to treat the underlying cause of inflammation in a fetus,” said Dr. Menon. This technology can also be used to package other drugs in exosomes to treat other adverse pregnancy complications.
This study result is the second proof of concept that suggests significant anti-inflammatory effects of the same exosomes from ILIAS Biologics. In April 2020, the researchers at Korea Advanced Institute of Science and Technology (KAIST) and the ILIAS team published the same exosomes’ substantial efficacy in the septic mouse model in Science Advances.
Extracellular Vesicle-Based Drug Delivery Systems
EVs are small membranous vesicles that are naturally produced and excreted from numerous cell types. EVs circulate through all bodily fluids and play a major role in intracellular and intercellular communication due to their multi-functional components such as proteins, DNAs, microRNAs, and mRNAs [52–54].
EVs’ ability to exchange genetic material with recipient cells can induce phenotypic modifications, making them a potential candidate in drug delivery systems for therapy [55]. Since EVs mediate cell-to-cell communication, they play critical roles in regulating the multiple facets involved in the pathogenesis of numerous diseases [56–58].
EVs may pathologically function as vehicles in drug treatment to disrupt communication pathways in pathogenesis to slow or alter disease progression [59].
EV Background
EVs are classified based on the size and biogenesis pathway. The three major clas- sified subgroups of EVs are exosomes, microvesicles (MVs, also called microparticles), and apoptotic bodies, and their internal contents consist of lipids, proteins, and nucleic acids [60,61].
Exosomes, MVs, and apoptotic bodies all contain distinct proteins that indicate their biogenic pathways and specific functions [62]. Exosomes range from about 30–150 nm in diameter. However, exosome size distribution and zeta potential can vary sig- nificantly among preparations from different isolation methods [63].
Exosomes are formed by the inward budding of the membrane of early endosomes that eventually mature into multivesicular bodies [62]. Since exosomes originate in the endosomal pathway, they are enhanced with protein chaperones, scaffolding proteins, and proteins for endosomal trafficking [64]. Researchers initially believed that exosomes’ biological purpose was to expel unwanted material from cells.
However, it has been discovered that they participate in cell maintenance, cell-to-cell communication, and tumor progression [59,62,65,66]. Microvesicles are derived from the outward budding of a cell’s plasma membrane [64,67], while apoptotic bodies are formed only during programmed cell death and generated through cell fragmentation and plasma membrane blebbing of apoptotic cells [67,68].
MVs can range from 50 to 1000 nm in size, and their formation is not well understood, but it is hypothesized that cytoskeleton components are required for their formation. Similar to exosomes, the biological purpose of MVs is to participate in cellular communication between local and distant cell types. Apoptotic bodies range from 50 to 5000 nm in size and are excreted by dying cells.
They are formed when the cytoskeleton and plasma membrane separates due to increased hydrostatic pressure induced by cell contraction [62]. Various isolation methods have been developed to potentially overcome the challenges associated with EV isolation, such as EV heterogeneity and biochemical property overlap, that may inhibit effective EV isolation [69–75]. Some of the developed techniques include ultracentrifugation, density gradient centrifugation, exosome precipitation, antibody-based immunoaffinity purification, tangential flow filtration, and nano-flow cytometry. EV differ- entiation in various extracellular environments remains the main challenge of inefficient EV isolation in clinical settings and has to be overcome for these techniques to be clinically reproducible [62].
Drug Loading in EVs
Parental cells determine the biological structure and function of EVs in vivo. While some biological features of EVs are currently known, further exploration, especially about ensuring the safety and efficacy of drug-loaded EVs, must precede future therapeutic applications. The specific approaches used to load EVs will also affect drug-loading capacity and the lifetime of drug-loaded EVs Based on the understanding of the biological features of EVs, there are two major methods of drug loading:
- (I) endogenous drug loading
- (II) exogenous drug loading. To minimize the elimination and degradation of EVs, the selection of drug loading method is pivotal.
Endogenous Drug Loading
Endogenous drug loading methods aim to optimize drug cargo compartmentalization into EVs through the nonspecific binding of drugs to the cytoplasmic membrane of donor cells [76]. In this method, desired cargos are simply incubated with EV-secreting cells. Readily, cargos may passively diffuse across the cell membrane and these cells then secrete EVs loaded with the desired cargo [77,78].
This drug-loading technique is a relatively straightforward strategy that involves a step-by-step process to load drugs by manipulating the donor cells [76]. Endogenous drug-loading strategies rely on the natural mechanisms of EVs to package drug cargo more efficiently. For endogenous loading, donor cells are exposed to the drug of interest, which is followed by stimuli such as heat or hypoxia to induce the release of drug-loaded EVs [76].
EVs are hypothesized to be proficient candidates for drug delivery systems due to their endogenous origin and internal structures. EVs contain intrinsic biological functions and internal cage-like structures that are ideal for containing and delivering drug loads to specific molecular targets [79]. They also possess an aqueous core and lipophilic shell formed by the lipid bilayer, creating two internal compartments. The lipid bilayer gives EVs the amphiphilic nature that allows them to store and dissolve hydrophobic and hydrophilic compounds, making them desirable for use in drug delivery systems [80].
Exogenous Drug Loading
To utilize EVs as drug carriers, an alternative approach for loading desired cargos into EVs can be achieved after EV isolation as an exogenous drug loading method. This method involves the isolation of EVs and subsequent drug loading or desired cargos in EV using mechanical approaches. Exogenous drug loading techniques vary depending on the target molecules of interest such as proteins, small molecules, and nucleic acids- specifically miRNA.
Some of the mechanical methods used to load desired cargos into EVs include incubation at room temperature, electroporation, sonication, transfection, saponin permeabilization, and mechanical extrusion [78,81–84]. Electroporation, the guidance of proteins and signature sequences, producing hybrid EVs with lysosomes, transfecting donor cells, and transfection with commercialized reagents, are methods to load nucleic acids into EVs [81].
Drug-loading strategies include incubation, ultrasonic treatment, eddy current oscillation, and direct mixing [78,83,84]. Ultrasonic treatment was discovered to have increased the drug paclitaxel’s load capacity and supported the release of EVs excreted by macrophages [81]. The disadvantage of passive loading methods includes the degradation of exosomes due to multiple purification steps.
The physicochemical properties of drug molecules can affect the stability and bioactivity of EVs [81].
While most cells produce EVs, not all cell-derived EVs are ideal drug carriers. Drug capacity and efficient delivery depend on the size, yield, intracavitary composition, and surface protein(s) [85].
EV biogenesis is a major factor determining the drug-loading ca- pacity of the various types of cell-derived EVs. Since EVs encompass some of their parent cell contents during biogenesis, there is limited space for endogenous and exogenous drug loading [85].
Passive drug-loading strategies used in concentration gradient-based strategies, such as electroporation or sonication, result in low loading efficiency. To compen- sate for the low loading efficiency, researchers have opted for active loading strategies to target exosome membranes during exosome biogenesis [86]. Exosomes are enhanced with transmembrane proteins that can be fused to cargo molecules to localize these molecules in exosomal cytosol [86]. The heterogeneous internal components and chemical lipid composition can influence drug compatibility with EVs, affecting the drug-loading capacity.
Pre-loading methods, post-loading methods, and drug hydrophobicity are factors influ- encing drug-loading capacity. For instance, researchers have found an 11-fold increase in drug-loading efficiency with the use of membrane permeabilizer saponin and hypotonic dialysis [85,87].
Researchers have taken a comparative approach to assess which method results in a higher loading efficiency. Porphyrins (of different hydrophobicities) served as the model drug that was encapsulated and loaded into EVs via dialysis, extrusion, electroporation method, and using saponin [87]. Hydrophobic compounds were loaded more efficiently in EVs via active methods than by using a passive incubation loading method [87]. Loading drugs into EVs resulted in a cellular uptake greater than 60%, and the photodynamic effect of hydrophobic porphyrins was greater in comparison to drug-loaded liposomes [87].
EV-Based Drug Delivery for Neurodegenerative Diseases
As we learn more about EVs and their potential roles in the human body, new oppor- tunities for the use of EVs as therapeutic agents have risen. The ability of EVs to penetrate the BBB and transfer cellular components between the CNS and the peripheral circulatory system suggests promising applications in many neurodegenerative diseases, such as AD, PD, MS, HAND, TBI, as well as COVID-19-associated brain damage [53,88–91].
AD
AD is a progressive neurodegenerative disease that is associated with dementia in the elderly [92]. AD pathogenesis is not yet completely clear. Many studies suggest that AD is characterized by the coexistence of two hallmark pathways that lead to the functional loss of synapses and neurons: the accumulation and disposition of insoluble Aβ plaques and the hyper-phosphorylation of tau proteins (P-tau), in addition to oxidative stress, cholinergic dysfunction, and inflammation [88,93,94].
Aβ plaque formation hinders synaptic plasticity, leading to neuronal apoptosis. This usually begins years before the appearance of any symptoms [92]. P-tau spread occurs after Aβ plaques are formed, and it is shown to affect specific sensors or motor functions in the brain, which is responsible for the loss of cognitive skills in AD patients [88,92]. Accumulating evidence suggests that EVs have a neurotoxic role in the propagation of AD, since amyloid precursor protein (APP)-metabolites, including Aβ, were found tied to exosomes, which are a subset of EVs [95].
Furthermore, Aβ plaques were found to be enriched with proteins that are associated with EV composition [95]. Studies have also indicated that the extent of neuronal loss is associated with EV levels in CSF [95]. EVs were also investigated in AD for their protective role as potential therapeutic agents [95,96].
For instance, cystatin C-loaded EVs have a neuroprotective role, and low serum cystatin C was detected in sporadic AD clinical presentation [95]. Different studies have suggested that EVs derived from human CSF may reverse the synaptic plasticity by disrupting the activity of Aβ plaques [95]. Another suggestion was to use short interfering RNA (siRNA)-loaded EVs against beta-secretase 1 to help decrease Aβ plaque formation [93,95].
Finally, studies have shown that the inhibition of EV release in AD animals using a neutral sphingomyelinase inhibitor (GW4869) has therapeutic benefits [97–99]. However, it also has undesired side effects associated with EV inhibition [97,100,101]. Nevertheless, the evidence is promising for EV use as early diagnostic biomarkers and potential therapeutic agents in AD.
PD
PD is the second most common neurodegenerative disease among the elderly [102]. PD is a progressive movement disorder associated with neuronal death in different regions of the brain [103]. PD is characterized by the progressive loss of dopaminergic neurons in the substantia nigra pars compacta and over-expression and aggregation of misfiled α-Synuclein (α-Syn) proteins, which is the primary constituent of Lewy bodies [104,105].
α-Syn can be transmitted from either the CNS or peripheral blood monocytes to the brain via EVs. Even though PD is a neurodegenerative disease, α-Syn levels in blood erythrocytes were higher than in the CSF by about 10-fold [103]. The α-Syn proteins within peripheral red blood cells (RBCs) can cross the BBB and be taken up by microglia into the brain parenchyma via EVs (RBC-EVs) [103].
The same study has indicated that systemic inflammation increases BBB permeability, which in turn increases the RBC-EV influx, leading to the development of PD. Further, the uptake of RBC-EVs by microglia enhances microglial inflammatory responses, leading to an increase in neurodegeneration [103]. In a 6-hydroxydopamine (6-OHDA)-treated mouse model of PD, significant anti-inflammatory and neuroprotective effects were observed following the intranasal delivery of catalase- loaded EVs. The same approach can be explored to deliver therapeutic proteins across the BBB for the treatment of various neurodegenerative diseases [106].
To date, there is no curative treatment for PD, which is one reason why early diagnosis using EVs as biomarkers has been a major topic of interest in disorders such as PD [102,107]. The promising accumulation of evidence suggests that EVs can be loaded with therapeutic agents and engineered to target a specific neuronal population [102,108].
MS
MS is a demyelinating autoimmune disease for which there is currently no effective re-myelination therapy [109]. However, a recent study found that in addition to EVs’ ability to cross the BBB, EVs are mediators in the axon myelination process [110]. In this study, EVs derived from mesenchymal stem cells (MSC-EVs) were demonstrated as feasible potential immunomodulatory agents and tissue repair mediators.
Another study in 2019 has discussed the potential use of EVs as prognostic and diagnostic biomarkers for MS [111]. In the same study, an immune marker array was used to identify EV surface proteins to differentiate MS patients and healthy controls. Toll-like receptor-3 (TLR3) was found in lower concentrations in MS patients than in controls, while TLR4 was higher in MS patients [111]. Although it is still too early to say that EVs can be drug delivery agents or even diagnostic biomarkers in MS, the evidence is promising.
HAND
HAND, which comprises different forms of neurocognitive impairments, is a grow- ing concern among HIV populations [112]. Although the lifespan of people living with HIV has been prolonged since the discovery of antiretroviral therapy, HIV infection still promotes premature aging due to its persistent infection in the CNS glial cells, which can induce HIV-1 associated dementia [113–115].
EVs from HIV-1 infected cells were found to carry viral neurotoxins such as gp120, Nef, and Tat, which can cause cell death, BBB disturbance, as well as induce HAND [88,116–120]. EVs carrying HIV-1 Nef released from infected cells have been shown to promote latent HIV-1 reactivation [121,122]. Platelet and megakaryocyte-derived EVs render the cells susceptible to HIV-1 infection by transferring HIV co-receptors such as CXCR4 and CCR5 [123,124].
HAND presentation is very similar to AD, especially because AD hallmarks such as Aβ plaque accumulation and hyper- phosphorylated P-tau were detected in both AD and HAND [125]. However, in HAND, EVs carrying Tat may induce Aβ plaque accumulation, increase BBB permeability, inhibit the effect of Aβ peptide degrading enzyme (neprilysin), and inhibit the Aβ clearance mechanism by inhibiting the phagocytic activity of microglia [126–128].
EVs are being investigated to be used in HAND patients due to their ability to cross the BBB [129]. For instance, Tat-induced EV-Aβ and EV-tau could be drug targets for caffeine, as caffeine was studied to inhibit both Tat-induced Aβ production and tau phosphoryla- tion [130,131].
Another example and potential intervention is the use of rapamycin-loaded EVs to modulate autophagy in the CNS in HAND patients. Early autophagy induction via rapamycin treatment showed promising results in reducing plaques, tangles, and cognitive deficits in preclinical AD models [132]. EVs are also explored as a potential diagnostic marker for cognitive impairment. Neuron-derived EVs are shown to be present at a significantly lower quantity in HIV individuals with neurocognitive impairment. Fur- thermore, these individuals had higher levels of high mobility group box protein 1 and Aβ in neuron-derived EVs [133].
TBI
The use of EVs as diagnostic biomarkers also promises to fill the diagnostic accuracy gap in many different diseases, such as in TBI [134]. A recent study used miRNA EVs and GluR2+ EVs to identify TBI presence, severity, recovery, and history of prior injuries [135]. Moreover, AD biomarkers, such as Aβ and P-tau concentrations, were higher in EVs that were isolated from TBI patients than from controls [134,136].
Additionally, EV-tau and Aβ42 were higher in patients with a history of multiple TBIs. Furthermore, EV neuro- filament neuropolypeptide and glial fibrillary acidic protein were associated with TBI diffusion and recovery [134]. Unresolved or dysregulated immune responses after TBI can contribute to chronic activation of neurotoxic microglia, eventually leading to progres- sive neuronal cell death [137].
Following TBI, activated microglia/macrophages release microparticles/microvesicles that propagate the injured brain’s neuroinflammatory re- sponses by further activating the neighboring microglia [53]. Thus, inhibiting EV secretion is warranted to regulate the over-activated innate immune responses by microglia during brain injury. Studies indicate that glial cell activation and the regulation of innate immune responses can be achieved either by blocking EV biogenesis or by the neutralization of EVs using nSMase inhibitors and the novel surfactant polyethylene glycol telomere B, respectively [53,138].
COVID-19 Associated Brain Damage
Mounting evidence suggests that the novel 2019 coronavirus disease (COVID-19) is neurotropic, as it is a viscerotropic disease [139]. COVID-19-related brain damage is associated with cytokine overproduction and toxicity, perhaps by delivering the virus and/or inflammatory/oxidative components to the CNS via EVs [30,139,140].
COVID-19 causes a broad variety of neurologic complications, such as hemorrhagic and/or ischemic strokes, seizures, and encephalopathy, which predicts a direct relationship between viral tropism and CNS injuries [139]. Presently, treatment options for COVID-19 are still being investigated, including the use of EVs as unique drug targets and carriers [30]. Moreover, EVs can be used in the treatment of COVID-19-associated brain damage due to their unique ability to penetrate the BBB and their potential to be engineered and targeted to a specific part of the CNS.
EV-Based Therapeutic Approach
EVs as therapeutic drug carriers are currently undergoing clinical trials for the treat- ment of pathogenic diseases such as cancer, autoimmune diseases, and neurodegenerative diseases [36,141]. EV-based drug delivery systems harness promising results due to their diverse cell-based origins and their ability to modulate various cell communication path- ways (Table 2).
Cargo loading methods, tissue targeting, the functional delivery of cargo to recipient cells, and the promotion of EV stability are strategic issues that are considered when choosing therapeutic agents for disease treatment [142]. Some therapeutic strategies may utilize EVs’ natural properties, such as pathogen suppression, immune modulation, or regeneration promotion, to improve the outcome of treatment by slowing pathogenesis or weakening autoimmune responses [142].
Data from recent clinical trials highlight that the importance of EVs as therapeutic delivery systems lie in the EV features, including cellular interactions, bio-distribution, circulation time, different cargo loading methods, and administration [143]. Drugs that could specifically benefit from EV drug delivery systems include anti-inflammatory agents and small RNA therapeutics [36,143–149].
Several human tumors originate in the epithelium and exhibit high epidermal growth factor receptor (EGFR) expression, hinting that EGFR could be a target in cancer drug delivery systems [150]. Nucleic acid drugs have promising therapeutic potential, but there are limitsto their clinical application due to a lack of efficient drug delivery systems [151–153].
Ohno et al. demonstrated that exosomes can act as an effective drug delivery system of miRNA to EGFR-expressing breast cancer cells [150]. The profile and biocompatibility of exosomes make them ideal in miRNA drug delivery because they are the natural carriers of miRNA.
In a preclinical study, MSC-EVs have been shown to promote neurogenesis, neurite re- modeling, and synaptic plasticity in an experimental rat model of ischemic stroke [154], as well as improvement in sciatic nerve regeneration in rats [155]. Given the beneficial effects of MSC-EVs in many preclinical models, MSC-EV therapy was given to patients with graft-versus-host disease (GvHD). Shortly after the start of MSC-exosome therapy, clinical GvHD symptoms were found to be significantly improved [156]. Systemically administered MSC-EVs improved impaired function and structural injury in the fetal ovine brain following hypoxia-ischemia [157].
Monocyte-derived myeloid cells play a central role in inflammatory/inflammation- related autoimmune diseases. Studies have been conducted to test the efficiency of exo- somes as drug delivery vehicles of anti-inflammatory agents [158]. Sun et al. examined EVs, specifically exosomes, as promising agents for delivering curcumin, an anti-inflammatory drug, to target inflammatory cells [158].
Curcumin is a natural polyphenol derived from the rhizome of Curcuma longa (turmeric) and known for its chemopreventative, antineo- plastic, anti-inflammatory, and antioxidant activity [158,159]. However, curcumin’s low solubility remains a major issue due to its hydrophobic properties. To increase exosome encapsulation efficiency, curcumin was mixed with EL-4-derived exosomes, resulting in the solubility of exosomal curcumin five-fold higher than free curcumin [158].
In order to de- velop an exosomal-based delivery system to treat PD, a potent antioxidant enzyme catalase was loaded into exosomes ex vivo. Following intranasal administration, catalase-loaded exosomes demonstrated significant neuroprotective effects in an in vitro and in vivo model of PD [106].
Limitations of EV-Based Drug Delivery Systems and Current Advancements to Counter these Limitations
Exosomes have potential advantages in drug delivery. While the application of exo- somes as drug delivery systems appears realistic in humans, there are still some challenges that lie ahead. For example, the problem of manufacturing large-scale batches of exosomes for clinical use remains unsolved. Furthermore, the production of homogenous EVs is challenging, as EVs produced from the same cell source have varied sizes [78]. These limitations need to be overcome in order to improve the feasibility of using EV-based drug delivery systems.
Interaction of Drugs with EV Components
Since EVs may serve as an ideal drug delivery system in CNS disease by crossing the BBB and delivering proteins, RNAs, DNA, and chemical drugs, various techniques are used for the loading of therapeutic agents inside EVs. However, various drug-metabolizing enzymes and drug transporters have been shown to be expressed in EVs [162].
These en- zymes pose challenges in terms of the stability of drugs, especially small molecules, which can be metabolized and effluxed out of the EVs. Cytochrome P450 (CYP) enzymes are the major metabolizers of xenobiotics, including therapeutic drugs [162]. Recently, Kumar et al. have shown a significant expression of functional CYP enzymes in EVs derived from hu- man plasma [163].
Further studies have demonstrated that various CYP enzymes, mostly expressed in the liver and immune cells, are packaged in EVs and eventually secreted in plasma [163]. Plasma EVs circulate in the periphery and perhaps in the CNS. They likely interact with other cell types by releasing these CYP enzymes.
The further induction of CYP enzymes in cell-derived EVs, upon exposure to xenobiotics such as tobacco and alcohol, suggests the role of these EV CYP enzymes in drug metabolism in extrahepatic cells [164–166]. Similarly, efflux transporters, such as p-glycoprotein (P-gp) are expressed in cell-derived EVs and circulated via plasma [30].
These studies suggest that CYP en- zymes and efflux transporters not only metabolize/transport xenobiotics in the liver and gut but can also clear toxic compounds, endogenous compounds, and therapeutic drugs in other extrahepatic cells/organs and the peripheral circulation.
Therefore, a complete understanding of various EV components, including CYP enzymes and efflux transporters, is important to predict the stability of drugs encapsulated in EVs derived from various sources. Upon understanding the role of CYPs and transporters in EVs of various cell types, EVs can be isolated from a source that is devoid of these enzymes.
Alternatively, drugs can be loaded along with CYP and P-gp inhibitors as pharmacoenhancers to inhibit/reduce the effects of these enzymes on the metabolic stability of loaded drugs. For example, being strong inhibitors of the CYP3A4 enzyme, ritonavir and cobicistat are known pharmaco enhancers of antiretroviral drugs [167], which can be used to co-formulate drugs that are CYP3A4 substrates.
In addition to efflux and metabolic stability, it is also important to study the interaction of small molecules and metals present in EVs with various drugs. For example, it is known that metals such as calcium interact with antibiotics such as doxycycline or minocycline, leading to reduced drug bioavailability [168].
Thus, antibiotics encapsulated in EVs isolated from milk (an easy source of EVs) are likely to interact with calcium and reduce the chemical stability of the drug. Similarly, EVs derived from lung alveolar macrophages may have various inhaled xenobiotics such as air pollutants, EVs derived from liver may have numerous stable xenobiotics obtained from food, and EVs derived from immune cells may have many small immune molecules. These small molecules are likely to interact with various drugs encapsulated in EVs isolated from their respective cells. Therefore, before developing EV-drug formulations, it is imperative to examine whether small molecules and metals present in EVs can interact with encapsulated drugs and reduce their stability. Thus, drug loading can be tailored to EVs isolated from cell types that do not have small molecules with the potential to interact with specific drugs.
Using multiple drugs simultaneously confers a high likelihood of producing drug– drug interactions (DDI) via CYP enzymes present in EVs. Many drugs are not only substrates, but they are also inhibitors and/or inducers/activators of CYP enzymes. Thus, DDIs occur as a result of the inhibition or induction/activation of CYP enzymes. Although most CYP enzymes are predominantly expressed in the liver, they are found to be packaged in EVs/exosomes and circulate with plasma.
For example, CYP2E1, which is highly abundant in plasma EVs [168,169], causes a DDI between alcohol and acetaminophen, leading to hepatotoxicity. An overdose of alcohol and/or acetaminophen, as well as drinking alcohol while taking acetaminophen, will increase the risk of adverse drug reactions.
Toxicity is not only expected in hepatocytes but also in extrahepatic cells, including CNS cells, via the circulation of EV CYP2E1. The expression of CYP enzymes also shows genetic variability. Thus, when using EVs/exosomes to deliver a drug, the interactions between drugs and the presence of polymorphic CYP enzymes should also be cautiously considered.
In Vivo Pharmacokinetics of EV Drugs
With greater attention paid to the potential of EV drug applications, a few EV drugs are currently undergoing clinical trials. The pharmacokinetics of EV drugs limit the efficacy and efficiency of EV drugs. Therefore, the administration method of EV drugs is an important step that governs the distribution of EVs into targeted sites or cells.
Intravenous Injection (IV)
The size of EVs is one of the factors that determines the pharmacokinetics of EV drugs. When intravenous injection is performed, only EVs smaller than 100 nm diameter can move with RBCs, with a small fraction of accumulation near the vascular wall. This indicates that smaller EVs are more appropriate for drug delivery purposes. After intravenous injection into the mouse model, EV levels immediately reduce and aggregate in the liver [169]. As a result, the majority of EVs circulating with RBCs in vivo are cleared by the liver and the spleen.
DiD lipid dye-labeled MSC-EVs were injected into the tail vein of mice and were mainly captured by the liver, spleen, and bone marrow as observed in vivo imaging, with the strongest fluorescence in the liver and spleen of mice [170]. The biodistribution results from a different group show that the source of EVs is related to the distribution sites in mice [171]. The diameter of EVs has been shown to affect biodistribution, with EVs < 100 nm able to move through the liver without significant uptake by hepatocytes [172]. Blood con- centrations and circulation kinetics of EVs also limit their pharmacokinetics. Macrophages identify the apoptotic signal on the EV membranes and promote clearance. Inhibiting the clearance of macrophages can maintain certain concentrations of EVs and prolong the circulation time of EVs in vivo [173].
Intraperitoneal Injections, Subcutaneous Injections, and Oral Administration Compared to intravenous injection, after the intraperitoneal or subcutaneous delivery
of HEK293T exosomes, they accumulate in the liver, gastrointestinal tract, or pancreas [174]. It is feasible to increase the concentration and duration of exosome efficacy on the target organ by the local administration. The direct injection of EVs through intranasal delivery can prevent EVs from entering the systemic circulation and being cleared in large amounts by the liver and spleen [175]. Oral administration is one of the potential methods for EV administration without invasive injury. In contrast to intravenous injection, the oral administration of milk-derived exosomes improved immune function and reduced arthritis in mice [176].
Delivery of Drugs to the Target
The drug delivery system design depends on the structure of a drug molecule, its formulation, administration approach, dosage form, and other related techniques. The recent development in drug delivery systems focused on nanoparticles can increase the drug concentration in targeted parts of the body. Exosomes can be widely detected in many body fluids. Unlike other artificial nanoparticles, exosomes are naturally generated in vivo, which makes them an ideal drug delivery vehicle with a longer half-life, lower toxicity, and more specificity to targeted tissues [177,178]. Compared with synthetic drugs, drug-
loaded exosomes are safer, stable, and biocompatible, due to their phospholipid bilayer structure [179]. The bio functional cargoes of exosomes range from nucleic acids, proteins, and lipids to synthetic drugs [180,181]. The uptake of exosomes has three steps: interactions between receptor and ligand, membrane fusion, and endocytosis/ phagocytosis [182]. The uptake of exosomes relies on one cell type and surface proteins of exosomes [183].
Some studies show that receptor–ligand interactions enhance the biological efficacy of exosomes, especially in cancer therapy [184] and modulating immune responses [182].
Researchers showed that exosomes delivered miRNA efficiently to EGFR-expressing breast tumor cells in a mouse study [150]. Due to this feature, exosomes can be poten- tially developed as diagnostic biomarkers. On the other hand, it has been proven that exosomes from neural stem cells recognized by the Ifbgr1 receptor on target cells are indis- pensable to maintaining the Signal transducer and activator of transcription 1 pathway’s activation [185].
Immune Clearance
Although the phospholipid bilayer structure of EVs makes them more biocompatible, elimination can happen before EVs arrive at the target cells. Most of the elimination is initiated by innate immunity. When exosomes are intravenously injected into mice, they are instantly cleared by the reticuloendothelial system before they reach the target tumor tissue [186]. Sinus CD169+ macrophages have been shown to suppress cancer progression by eliminating the tumor-derived exosomes before they interacted with B cells [187].
Exosomes can also regulate innate immunity. Tumor-derived exosomes can negatively regulate T cell immunity by raising adenosine levels when expressing CD39 and CD73 [188]. Thus, further study to understand the immune clearance of EVs, as well as the development of necessary steps to counteract immune clearance, is needed. One such approach could be the isolation of EVs from the plasma of patients, drug loading in these EVs, and injecting drug-loaded EVs back to the same patients. This personalized medicine approach may have the ability to eliminate/reduce unwanted and adverse immune reactions.
Conclusions
This review presents recent advances in a biomaterial-based drug delivery approach for the controlled delivery of drugs or desired cargos to prevent or treat neurodegeneration in the CNS. As previously stated, biomaterials exist in different types; however, their use in clinical application is limited due to intensive interaction with the body tissue. Meanwhile, EVs possess numerous advantages over biomaterials in the context of a safe and effective drug delivery approach (Figure 1).
In contrast to liposome-assisted drug delivery, EVs manifest higher loading efficiency and loading capacity for chemical drugs, and being natural nanoparticles, they are biodegradable and not expected to have adverse effects. The natural ability of exosomes to carry biological molecules such as long and short nucleic acid, proteins, and small molecules, as well as their ability to regulate gene expression and the phenotypic modifications of recipient cells make them an ideal drug-delivery modality.
EVs not only demonstrate lower toxicity and lower immunogenicity than other drug delivery strategies but also bear specific surface proteins that can guide themselves to target organs.
Due to the physiological role in various cellular functions, EVs have the potential to act as an ideal drug delivery system for neurodegenerative diseases by crossing the BBB and delivering desired cargos that include chemical drugs to the CNS. Under appropriate conditions, drugs that possess a hydrophobic or lipophilic nature or molecules such as antioxidants, anticancer, or anti-inflammatory drugs can be encapsulated into EVs.
However, to intensify the bioavailability and efficacy of drugs with complicated properties, the successful integration of these drugs into EVs is required. In several studies, the delivery of target genes and selective silencing of genes aided by siRNA- loaded EVs has been validated. However, before we realize the full potential of EV-loaded drugs for therapeutic applications, certain limitations involving drug stability, in vivo
pharmacokinetics, drug targeting, immune clearance, and the production of large-scale sterile preparations must be overcome.
reference link: https://dx.doi.org/10.3390/ijms 22010138
More information: Samantha Sheller-Miller et al, Exosomal delivery of NF-κB inhibitor delays LPS-induced preterm birth and modulates fetal immune cell profile in mouse models, Science Advances (2021). DOI: 10.1126/sciadv.abd3865
